Skip to Main Content

Clinical Studies and Protocols

Site Map Investigators Log-in
(JKR-0968) Defining reversal of alopecia areata (AA) phenotype with dupilumab in patients with and without associated atopic dermatitis (AD)


 Return to List of Clinical Studies
 Return to List of Protocols for Psoriasis and Skin Diseases
Defining reversal of alopecia areata (AA) phenotype with dupilumab in patients with and without associated atopic dermatitis (AD)

Principal Investigator:
James G. Krueger M.D., Ph.D.

Investigators:

Contact Information:
Clinical Research Support Office
1230 York Avenue
New York, NY 10065
Telephone: 1.800.RUCARES
Email: RUCARES@Rockefeller.edu
Enrollment Status:
Open to Enrollment

Brief Summary of Protocol:
The purpose of this study is to assess whether dupilumab can be a helpful treatment for alopecia areata (spots of hair loss caused by your immune system). Dupilumab is investigational for the purpose of this study as it is not FDA-approved for the treatment of alopecia areata, but it is FDA approved for the treatment of moderate to severe atopic dermatitis in adult patients.



Detailed Description of Protocol:
Participating in this study includes the following: Physical exams and your medical history including medications you take, blood tests for overall health and safety, and research blood tests to measure substances in your body responding to the study medication, up to 6 skin biopsies of skin affected by alopecia areata and normal skin; if you have atopic dermatitis we would also like to biopsy skin affected by that disease; medical photographs of your affected skin and pregnancy testing for female participants.



What specifically makes a person eligible for the study?
You may be eligible to enter this study:

You may qualify to take part in this research study because you have alopecia areata, alopecia areata and atopic dermatitis, and are at least 18 years old. We expect one third of participants will have atopic dermatitis in addition to alopecia areata.

Gender:
Both

Age(s):
18-99

Children permitted to participate:
No

Potential Benefits.....
Your disease may or may not improve during participation in this study.



Compensation:
Compensation is provided.